Alfred B. Engelberg is a retired intellectual property lawyer and philanthropist. During his legal career he was a Patent Examiner in the United States Patent Office, a patent trial attorney in the United States Department of Justice, and a member of the New York City law firm of Amster, Rothstein & Engelberg. As counsel to the generic drug industry, he played a major role in drafting the Hatch-Waxman Act of 1984 which created the modern generic drug industry. Subsequently, he specialized in litigation challenging the validity of patents claiming a number of commercially important prescription drugs. In recent years, Mr. Engelberg has been active as a writer, advisor, and speaker on policy issues related to affordable medicines and intellectual property rights in the United States and around the world.
In 1991, Engelberg founded the Engelberg Foundation as a charitable trust to provide grants for innovative health care, youth development, and social service projects. The Engelberg Foundation was instrumental in creating the Consumer Reports Best Buy Drug Program; the first Family Medicine residency program in Manhattan and a number of other health related programs in New York City. Engelberg was also the founder of The Engelberg Center on Healthcare Reform at Brookings; The Engelberg Center on Innovation Law & Policy at NYU School of Law; and has served as a Trustee of many non-profits. He is also a Fellow of the New York Academy of Medicine.
Recent Posts by Alfred Engelberg
The public has a right to expect that Trump will use that business prowess and the federal government’s leverage as the world’s largest purchaser of prescription drugs to stop the pharmaceutical industry from “getting away with murder” on drug prices.
Extra monopolies have caused US consumers to pay higher prices for medicines for longer periods of time while making the pharmaceutical industry far more profitable than any other industry. The next president and Congress should take several key steps to roll back costly, unnecessary monopolies.
Meaningful intellectual property ownership for older medications expired decades ago, and they are now subject to massive price increases or severe shortages. This need not be the case, and there are remedies to address these problems.
US law governing prescription pharmaceutical markets gives every new drug a long-term monopoly that prohibits competition. High prices and slow innovation cycles are the inevitable result and will remain so unless Congress makes fundamental changes in existing law.